Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02293096 · ClinicalTrials.gov registry record · NA
Pharmacogenetic Prediction of Metoprolol Effectiveness
A NA study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- NA
- Development phase
- 462
- Enrollment target
NCT02293096: Clinical Trial NA study, sponsored by University of Colorado, Denver.
NCT02293096 is a NA study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 462 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02293096, a NA study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- NA
- Development phase
- 462 participants
- Enrollment target
Study Summary
The investigators will prospectively follow a population of patients with uncontrolled high blood pressure beginning metoprolol succinate therapy to determine the drug effect in an observational clinical trial. The investigators will determine each individual's genotype for both CYP2D6 and Adrenoceptor Beta 1 (ADRB1). Metabolomic markers will be identified to determine if specific metabolites are associated with drug response. The investigators' overall objective is to determine if genetics predicts metoprolol succinate response better than clinical factors such as age, race, body mass index, dose, and medication co-ingestion.
Primary Outcome
Participants with at least a 10% decrease in SBP
Interventions
- GENETIC Genotyping
- DRUG metoprolol succinate
- PROCEDURE CYP2D6 Phenotyping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2014-09 |
| Est. Completion | 2017-08-23 |
| Phase | NA |
Why NCT02293096 stopped before completion
NCT02293096 is an interventional study that assigns participants to a tested intervention. The registered 462 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 3 interventions - of which Genotyping is the first listed.
NCT02293096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02293096 about?
NCT02293096 is a clinical study titled "Pharmacogenetic Prediction of Metoprolol Effectiveness". The investigators will prospectively follow a population of patients with uncontrolled high blood pressure beginning metoprolol succinate therapy to determine the drug effect in an observational clinical trial. The investigators will determine each individual's genotype for both CYP2D6 and Adrenocep...
What is the current status of trial NCT02293096?
This trial is currently terminated. It is a NA study. The enrollment target is 462 participants. The study started on 2014-09. Estimated completion is 2017-08-23.
What interventions are being tested in trial NCT02293096?
The interventions under investigation include: Genotyping (GENETIC), metoprolol succinate (DRUG), CYP2D6 Phenotyping (PROCEDURE).
Who is sponsoring clinical trial NCT02293096?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02293096's enrollment target sits among peer trials
462 222nd of 2000 higher than 1,779 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00949819 · 462 participants
Active Surveillance for Cancer of the Prostate (ASCaP)
- NCT05126277 · 462 participants · Phase 3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
- NCT04546399 · 461 participants · Phase 2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04787744 · 464 participants · Phase 2
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia